ArticleCardiology and therapy2026
Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy.
Article in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transthyretin Amyloidosis Outcomes Survey (THAOS): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin Gene Mutations or Wild-Type Transthyretin Amyloidosis.
A phase 3 multicenter, open-label study to evaluate the safety of daily oral dosing of tafamidis meglumine (pf-06291826-83) 20 mg or 80 mg [or tafamidis (pf-06291826-00) 61 mg] in subjects diagnosed with transthyretin cardiomyopathy (attr-cm)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDisease-modifying therapies for transthyretin amyloid cardiomyopathy (ATTR-CM) improve clinical outcomes, yet older patients are undertreated. In this analysis, we evaluated survival and cardiovascular-related hospitalizations (CVH) among patients treated with tafamidis (tafamidis free acid at 61 mg or bioequivalent tafamidis meglumine at 80 mg) aged < 80, 80-85, and > 85 years to assess effects of baseline clinical phenotype on outcomes.
methodsData were pooled from an early access cohort (ClinicalTrials.gov ID: NCT02791230) and the Transthyretin Amyloidosis Outcomes Survey registry (NCT00628745; enrollment 2019-2023; cardiac/mixed phenotype). Outcomes included all-cause mortality (ACM), CVH, and ACM or CVH. Cox proportional hazards and negative binomial regression models were adjusted for age, sex, TTR genotype, phenotype, New York Heart Association (NYHA) class, and estimated glomerular filtration rate (eGFR).
resultsAmong the 1924 patients enrolled in the study, 1188, 505, and 231 were aged < 80, 80-85, and > 85 years, respectively. Patients aged > 85 versus 80-85 and < 80 years had lower baseline mean eGFR (39.7 vs. 49.8 and 64.1 mL/min/1.73 m
conclusionPatients aged ≥ 80 years who were treated with tafamidis had outcomes comparable to those of younger patients when clinical vulnerability markers were considered. These findings support individualized treatment decisions based on patient's overall clinical profile and multidimensional assessment rather than age alone.
trial registrationClinicalTrials.gov identifiers: NCT02791230, NCT00628745.
Indexed as
Identifiers
42728504What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.